Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Inventory (2019 - 2025)

Historic Change in Inventory for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $72000.0.

  • Karyopharm Therapeutics' Change in Inventory rose 746.27% to $72000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$701000.0, marking a year-over-year decrease of 14133.25%. This contributed to the annual value of -$701000.0 for FY2025, which is 14133.25% down from last year.
  • Per Karyopharm Therapeutics' latest filing, its Change in Inventory stood at $72000.0 for Q4 2025, which was up 746.27% from -$1.0 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Change in Inventory peaked at $1.2 million during Q3 2024, and registered a low of -$1.0 million during Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' median Change in Inventory value was $2500.0 (recorded in 2022), while the average stood at $69700.0.
  • Its Change in Inventory has fluctuated over the past 5 years, first skyrocketed by 74380.17% in 2022, then crashed by 18578.6% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Change in Inventory stood at $77000.0 in 2021, then tumbled by 132.47% to -$25000.0 in 2022, then crashed by 148.0% to -$62000.0 in 2023, then surged by 208.06% to $67000.0 in 2024, then increased by 7.46% to $72000.0 in 2025.
  • Its last three reported values are $72000.0 in Q4 2025, -$1.0 million for Q3 2025, and $223000.0 during Q2 2025.